Boc-D-phenylglycinol, a protected D-phenylglycinol derivative with molecular weight 237.3 g/mol, is received as a white to off-white crystalline solid and recrystallized from n-heptane–ethyl acetate 4:1 v/v before use in multi-step API side-chain assembly. The N-tert-butoxycarbonyl group suppresses N-acylation during O-acylation and is cleaved only under controlled acidic conditions, which places the material between route-building and deprotection stages in peptide-mimetic and antiviral substance production. In a typical 500 L glass-lined reactor, the compound is charged at 1.0–1.1 molar equivalents relative to a carboxylic acid component, dissolved in anhydrous dichloromethane at 0.3–0.6 M, and cooled to 0–5 °C. The coupling is initiated with EDC hydrochloride 1.05–1.2 equivalents and HOBt monohydrate 1.0 equivalent, while N-methylmorpholine is added to maintain the internal pH at 8.0–8.5; the temperature is kept below 10 °C because the carbodiimide activation exotherm can induce premature Boc loss under localised acid build-up. After 6–12 h at 0–5 °C, dicyclohexylurea is removed by pressure filtration through a 10 μm cloth filter, and the organic phase is washed sequentially with 5% w/w citric acid, 7% w/w sodium bicarbonate, water, and saturated brine. The protected amido alcohol is crystallized by solvent switch into n-heptane:ethyl acetate 4:1 v/v, followed by cooling to -10 °C at a controlled ramp of 0.2 °C/min; isolated batches are dried under vacuum at 35 °C until water content falls below 0.5% w/w. The primary terminal products are N-Boc-protected amino alcohol intermediates that undergo subsequent sulfonylation, Mitsunobu displacement, or ester aminolysis, yielding β-amino alcohol-containing scaffolds for antiviral and protease inhibitor programs. For late-stage use, manufacturing and controls follow ICH Q7; starting material designation is justified under ICH Q11. Residual solvent compliance is evaluated against USP <467> Option 1, elemental impurities against USP <232> / ICH Q3D, and water content by USP <921> Karl Fischer coulometry. The specification for assay is ≥98.0% by HPLC area normalization, and enantiomeric excess is ≥99.0% by validated chiral HPLC. Operational boundaries include storage at 2–8 °C in tightly sealed containers, with re-drying required if the material is exposed to relative humidity above 60% RH for more than 12 h. The Boc group is stable under alkaline aqueous workup but is cleaved by trifluoroacetic acid or HCl/dioxane; therefore the compound must not be combined with strong acid streams before the intended deprotection step.

Where Does Enantiomeric Excess Deteriorate in Chiral Oxazoline Ligand Production?

Racemization of the α-carbon in amino alcohol-derived oxazoline ligands becomes detectable under Lewis acidic cyclization conditions when residual water exceeds 0.05% w/w. In production of 4-phenyloxazoline-containing phosphine-oxazoline ligands, Boc-D-phenylglycinol is carried through a protected precursor sequence to avoid O,N-bis-acylation. The free amine is liberated under HCl in ethyl acetate at ≤25 °C, isolated as the hydrochloride, and then treated with imidate hydrochloride 1.05 equivalents in anhydrous dichloromethane at -5 to 0 °C. Cyclization to the oxazoline ring is triggered by methanesulfonyl chloride 1.2 equivalents and triethylamine 2.5 equivalents, with an internal temperature ceiling of +5 °C; pilot batches exceeding +7 °C for more than 20 min showed rapid oligomerisation, an increase in kinematic viscosity from 1.2 mm²/s to 8.4 mm²/s, and isolated yield loss below 70%. Residual water must be held below 300 ppm because methanesulfonyl chloride hydrolysis produces HCl that cleaves the residual Boc group, leading to free amine that competes for acylation and lowers the chemoselectivity of the cyclization sequence. The enantiomeric excess of the oxazoline is monitored by chiral HPLC on a Chiralpak IA-3 column with UV detection at 210 nm, mobile phase n-hexane:2-propanol 90:10 v/v, flow rate 1.0 mL/min, and column temperature 25 °C; batch acceptance is ≥99.0% ee for ligand use. The molar addition ratio for the protected amino alcohol relative to imidate is 1.00 equivalent, with imidate used in slight excess to compensate for surface moisture on raw materials. Downstream process operations include quench with 5% w/w ammonium chloride, separation in a centrifugal extractor, solvent exchange to toluene, and crystallisation at -20 °C for 8 h. Terminal product types are diphenylphosphinooxazoline and tert-butylphosphinooxazoline ligands used in enantioselective allylic substitution and hydrogenation; these are not pharmaceutical substances but are intermediates for custom catalysis. Compliance applicable to these ligand outputs includes ICH Q3A when the ligand enters an API route; palladium content is controlled at ≤10 ppm by ICP-MS, and residual solvent reporting follows USP <467>. Published data for this specific configuration is limited at production scale; the temperature and moisture limits described derive from disclosed pilot batch observations rather than compendial monographs.

Silica functionalization with a phenylglycinol-derived chiral selector is performed on 5 μm fully porous spherical silica with surface area 300 m²/g and controlled pore diameter 100 Å. The silica is first activated at 140 °C for 12 h under nitrogen purge, then refluxed with aminopropyltriethoxysilane in dry toluene to generate an aminopropyl spacer at a loading of 0.8–1.0 μmol/m². The Boc-D-phenylglycinol is activated as a carbamoyl chloride or isocyanate intermediate and coupled to the aminopropylsilica in anhydrous N,N-dimethylformamide with triethylamine 0.1 mL/g silica at 80 °C for 16 h. Grafting density of the chiral selector is controlled between 0.6 μmol/m² and 0.8 μmol/m²; loadings above 0.9 μmol/m² create a dense bonded layer that restricts mass transfer and causes asymmetric peak tailing for aromatic amino alcohols under reversed-phase conditions. After the covalent bonding step, residual aminopropyl groups are endcapped with hexamethyldisilazane in toluene at 110 °C for 6 h, giving a carbon load of 8–12% C. The bonded silica is slurry-packed into 150 mm × 4.6 mm and 250 mm × 4.6 mm stainless steel columns at 600–800 bar using methanol:water 70:30 v/v as packing solvent. Terminal product types are Pirkle-type chiral stationary phases for analytical and preparative separation of small aromatic amines, β-amino alcohols, and α-arylpropionic acid derivatives; column efficiency is specified at ≥60,000 plates/m for a toluene probe under reversed-phase conditions. The formulation addition ratio is selector coverage 0.6–0.8 μmol/m², with silica-to-solvent slurry ratio 1:10 w/v and endcapping reagent excess 3 equivalents relative to residual silanol content. For validation and routine use, chromatographic methods are developed under ICH Q2(R1), system suitability is evaluated per USP <621>, and electronic batch data are maintained in accordance with 21 CFR Part 11. Operational boundaries: bonding above 90 °C can degrade the chiral selector via decomposition of the Boc group; residual triethylamine must be washed to below 0.05% w/w to avoid baseline drift in polar organic eluents.

Classical Resolution of Racemic Carboxylic Acids via Protected Amino Alcohol Esters

For racemic arylpropionic acid streams, Boc-D-phenylglycinol functions as a chiral resolving auxiliary through diastereomeric ester formation. The protected amino group prevents zwitterion formation and retains the auxiliary in the organic phase during extraction, which simplifies recovery after hydrolysis. In a 200 L reactor, the racemic acid is combined with the protected amino alcohol at 1.0 equivalent, DCC at 1.1 equivalents, and DMAP at 0.05 equivalents in anhydrous dichloromethane at 0–10 °C. The slurry is stirred for 4–6 h until HPLC shows ≤0.5% residual acid, then dicyclohexylurea is removed by filtration. The filtrate is solvent-exchanged to n-heptane:ethyl acetate 8:1 v/v and cooled to -12 °C over 3 h; the desired diastereomer is collected by centrifuge filtration. The purified ester is hydrolysed with lithium hydroxide 1.5 equivalents in THF:water 3:1 at 0–5 °C, releasing the resolved acid with ≥98.5% ee by chiral HPLC. The auxiliary is recovered from the aqueous layer after acidification and back-extraction into ethyl acetate; typical recovery is 70–80%. Terminal product types are enantiopure arylpropionic acid building blocks used in nonsteroidal anti-inflammatory pharmaceutical synthesis. Compliance for this operation includes USP <467> for residual solvents in the released acid, ICH Q3C for solvent classification, and HPLC control of residual auxiliary and deprotection impurities at ≤0.10% area each. If the resolved acid enters a GMP route, ICH Q7 applies to subsequent steps; lithium content is controlled at ≤20 ppm by ICP-MS. The method is unsuitable for base-labile acids or acids that racemize under LiOH hydrolysis, and the crystallization window is narrow because ester crystallization above -8 °C yields large diastereomeric impurity inclusions that reduce resolution efficiency.

When a Boc-Amino Alcohol Is Introduced at Oligopeptide Coupling pH Below 8.0

In solution-phase assembly of peptide-mimetic protease inhibitors, Boc-D-phenylglycinol is introduced as a C-terminal glycinol equivalent to produce a peptide alcohol that resists carboxypeptidase degradation. Coupling to a Cbz-protected tripeptide acid is performed in anhydrous DMF at 0.25 M using EDC hydrochloride 1.2 equivalents and HOBt monohydrate 0.8 equivalent. At pH 7.5, conversion remains below 50% after 4 h because the protonated amino group of the coupling reagent reduces active ester formation; at pH 9.0, conversion exceeds 90% within 1 h, but the free hydroxyl of the protected glycinol begins to cyclize onto the adjacent carbamate, producing oxazolidinone impurity. The production process therefore uses a two-stage pH sequence: initial pH 8.5 is held for 1 h to reach 60% conversion, after which acetic acid is added to reduce pH to 7.0 and suppress cyclization until the reaction completes at 4–6 h. Stoichiometry is peptide acid 1.0 equivalent, Boc-D-phenylglycinol 1.1 equivalent, EDC 1.2 equivalents, and HOBt 0.8 equivalent. Workup includes dilution with ethyl acetate, washes with 0.5 M citric acid and 0.5 M sodium bicarbonate, and silica plug filtration to remove polymeric urea byproducts. Terminal products are peptide alcohols with a D-phenylglycinol C-terminal mimic; after hydrogenolysis and acidolysis, these are advanced into hydroxyethylamine isosteres used in antiviral protease research. Compliance for these intermediates includes ICH Q3A impurity thresholds, ICH Q3C residual solvent reporting, and USP <621> HPLC system suitability; peptide content is ≥95.0%, enantiomeric excess ≥99.0%, and identity is confirmed by LC-HRMS. The central boundary is that residual acylating agents must be quenched within 30 min of complete conversion with aqueous bicarbonate; otherwise the free alcohol forms oxazolidinone and the isolated peptide alcohol content drops below 85%.